A Phase 3 interventional study of Calcitonin and Saline in Calcitonin, Subcutaneous and Acute Herpes Zoster, sponsored by Tanta University. Recruiting at 1 site in Egypt. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-07-06.
Sponsored by Tanta University · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This prospective randomized controlled study will be conducted to evaluate the effect of adding calcitonin to the standard treatment protocol in patients with acute herpes zoster infection.
Herpes zoster is associated with inflammation of the dorsal root ganglion and peripheral nerves, and this inflammation is considered to be an important causative factor for postherpetic neuralgia.
Interventions aimed at reducing this inflammation should therefore be effective in decreasing the likelihood of developing postherpetic neuralgia. Epidural administration of corticosteroids and local anesthetics has been shown to be effective, but is associated with the risk of arachnoiditis. Subcutaneous injection in an outpatient setting may be effective in preventing postherpetic neuralgia and is also considerably safer. Calcitonin has previously been shown to be effective in the management of acute pain following amputation. Also it was used in a previous study to prevent complex regional pain syndrome in severe hemiplegic patients after stroke. Also, a previous case report revealed that IV calcitonin provided immediate and sustained improvement in post herpetic neuralgia for over two months, without adverse effects from the calcitonin therapy.
However, no previous trials evaluated the effect of subcutaneous calcitonin as a preventive measure against the development of postherpetic neuralgia. We will conduct this study as we hypothesize that calcitonin therapy in patients with acute herpes zoster may be associated with better acute pain control and therefore may decrease the incidence of postherpetic neuralgia.
300 studies on the registry are indexed under Herpes Zoster; 56 are open to participants now.
This study's planned enrollment of 168 is close to the median of 160 across 248 interventional studies indexed under Herpes Zoster.
Browse Herpes Zoster studies →Tanta University is the lead sponsor of 1,015 studies on the registry; 321 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
patients will receive subcutaneous salmon calcitonin 100 IU (ampoule = 1 ml) daily for three weeks.
Drug: Calcitonin
patients will receive subcutaneous saline (1 ml) daily for three weeks.
Other: Saline
patients will receive subcutaneous salmon calcitonin 100 IU (ampoule = 1 ml) daily for three weeks
patients will receive subcutaneous saline (1 ml) daily for three weeks.
Incidence of postherpetic neuralgia at 3 months after rash onset.
A numeric rating scale (NRS) that ranged from 0 for "no pain" to 10 for "worst ever pain will be used to assess the degree of pain. Pain score more than (3) at 3 months after onset of acute herpes zoster rash will be considered positive for the occurrence of postherpetic neuralgia.
Time frame: 3 months after onset of acute herpes zoster rash.
Incidence of postherpetic neuralgia.
Pain score more than 3.
Time frame: 6 months after onset of acute herpes zoster rash.
Severity of acute herpes zoster pain.
A numeric rating scale (NRS) that ranged from 0 for "no pain" to 10 for "worst ever pain will be used to assess the degree of pain.
Time frame: Up to 1 month after onset of acute herpes zoster rash.
Number of medications used to treat pain.
Analgesics, anti-neuropathic pain medications and opioids will be recorded.
Time frame: up to 6 months after onset of acute herpes zoster rash.
Side effects
Vomiting
Time frame: Up to 1 month after onset of acute herpes zoster rash.
Plan to share: Yes — The data will be available upon a reasonable request from the corresponding author.
Supporting information: Study protocol, Statistical analysis plan
Time frame: After completion of the study.
Access criteria: The data will be available upon a reasonable request from the corresponding author.
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Apr 2027, 9 months after the start.
Of 40 phase 3 interventional studies under Herpes Zoster, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 45. This study's planned 9 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Calcitonin